The FDA granted 510(k) clearance for PhysIQ’s atrial fibrillation analytic designed to generate clinical insight from wearable biosensors.

The clinical insight the analytic generates can help clinicians reduce re-hospitalization rates and move towards personalized precision medicine for atrial fibrillation.

The analytic is intended to support both health systems and payers in addition to pharmaceutical and medical device companies that use wearable biosensors in their clinical trials.